New antituberculosis drugs targeting the respiratory chain

作     者：Qian Li Xiaoyun Lu Qian Li;Xiaoyun Lu

作者机构：International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education(MOE)School of PharmacyJi'nan UniversityGuangzhou 510632China 

出 版 物：《Chinese Chemical Letters》 (中国化学快报（英文版）)

年 卷 期：2020年第31卷第6期

页      面：1357-1365,F0003页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学] 

基　　金：financial support from the National Natural Science Foundation of China(No.81922062) Guangdong Provincial Science and Technology Program(No.2018A050506043)and Jinan University 

主　　题：Respiratory chain Antituberculosis drug QcrB NADH-2 ATP synthase 

摘      要：With the emergence of multidrug-resistant tuberculosis and extensive drug-resistant tuberculosis strains,there is an urgent need to develop novel drugs for the treatment of *** respiratory chain is a promising target for the development of newantimycobacterial agents,and a growing number of compounds have been reported and some have entered clinical *** this review,we summarize the main features and the electron transfer process of the mycobacterial respiratory chain,and the recent progress in the search for new small molecule inhibitors to rgeting the three main potential targets in the respiratory chain of Mycrobacterium *** emphasis is on the optimization strategy of QcrB inhibitors and the challenges of developing QcrB inhibitors as antituberculosis drugs due to the alternate bd-type oxidase oxidative compensation pathway are discussed.